Enhancing the Anti-Tumour Immune Response of Reovirus with Sunitinib for the Treatment of Multiple Myeloma

Simple item page
dc.contributor.advisorMorris, Don G.
dc.contributor.authorMeyers, Daniel E.
dc.contributor.committeememberMahoney, Douglas J.
dc.contributor.committeememberBahlis, Nizar Jacques
dc.date2020-06
dc.date.accessioned2020-01-15T21:22:40Z
dc.date.available2020-01-15T21:22:40Z
dc.date.issued2020-01
dc.description.abstractMultiple Myeloma (MM), a malignancy of plasma cells, is currently felt to be incurable. Current therapies such as monoclonal antibodies, immunomodulatory drugs, proteosome inhibitors, and autologous stem cell transplantation have substantially improved median overall survival over the past decade. However, despite the advent of these new therapeutic strategies the vast majority of MM patients relapse with therapy-resistant disease. The aim of this thesis was to determine the pre-clinical efficacy of reovirus (RV) as monotherapy and in combination with sunitinib (SUT) – a multi-tyrosine kinase inhibitor - for the treatment of MM. We utilized a syngeneic, immunocompetent, transplantable model of MM (Vk*MYC) for our lines of experimentation. Although our studies demonstrated that the addition of SUT to RV led to the modulation of immune subpopulations within the splenic tumour microenvironment, no clear data to support a definitive survival advantage with dual therapy were acquired. Despite the pre-clinical promise of RV for the treatment of MM, the addition of SUT does not appear to provide a survival advantage in this animal model. Given the modest of efficacy of SUT monotherapy in clinical studies of MM, this dual treatment approach should not be a priority for clinical investigation in MM at this time. Further pre-clinical studies are needed to better characterize the possible immunomodulatory role of SUT in MM.en_US
dc.identifier.citationMeyers, D. E. (2020). Enhancing the Anti-Tumour Immune Response of Reovirus with Sunitinib for the Treatment of Multiple Myeloma (Master's thesis, University of Calgary, Calgary, Canada). Retrieved from https://prism.ucalgary.ca.en_US
dc.identifier.doihttp://dx.doi.org/10.11575/PRISM/37458
dc.identifier.urihttp://hdl.handle.net/1880/111501
dc.language.isoengen_US
dc.publisher.facultyCumming School of Medicineen_US
dc.publisher.institutionUniversity of Calgaryen
dc.rightsUniversity of Calgary graduate students retain copyright ownership and moral rights for their thesis. You may use this material in any way that is permitted by the Copyright Act or through licensing that has been assigned to the document. For uses that are not allowable under copyright legislation or licensing, you are required to seek permission.en_US
dc.subjectOncolytic virusen_US
dc.subjectReovirusen_US
dc.subjectImmunotherapyen_US
dc.subjectMultiple Myelomaen_US
dc.subject.classificationOncologyen_US
dc.titleEnhancing the Anti-Tumour Immune Response of Reovirus with Sunitinib for the Treatment of Multiple Myelomaen_US
dc.typemaster thesisen_US
thesis.degree.disciplineMedicine – Medical Sciencesen_US
thesis.degree.grantorUniversity of Calgaryen_US
thesis.degree.nameMaster of Science (MSc)en_US
ucalgary.item.requestcopytrueen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ucalgary_2020_meyers_daniel.pdf
Size:
8.15 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.62 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Theses and Dissertations